Journals / Turkish Neurosurgery / 2013 / Cilt: 23 - Sayı: 6

Rat Spinal Kord Hasarında Rituksimabın Nöroprotektif Etkileri: Bir İmmünohistokimyasal Çalışma

The Neuroprotective Effects of Rituximab in Rat Spinal Cord Injury Model: An Immunohistochemical Study

Pages
783–790
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Antibodies against IL-1β, IL-6, TNF-α and CD20 were studied with the ELISA method together with electron microscopic analysis. results: It was found that rituximab suppressed oligodendrocytes at the phagocytic stage but was still inefficient for the regenerative phase.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIm: In the present study, we investigate the neuroprotective effects of rituximab, a monoclonal antibody directed towards B cell mediated humoral immunity, on a rat spinal cord injury (SCI) model with immunohistochemical methods. mAterIAl and methOds: Twenty-four rats were used for the study.
📊
Key Findings & Data:Intraperitoneal rituximab administration was performed on days 0, 3 and 5 in the third group.
💡
Conclusion & Impact:Antibodies against IL-1β, IL-6, TNF-α and CD20 were studied with the ELISA method together with electron microscopic analysis. results: It was found that rituximab suppressed oligodendrocytes at the phagocytic stage but was still inefficient for the regenerative phase.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIm: In the present study, we investigate the neuroprotective effects of rituximab, a monoclonal antibody directed towards B cell mediated humoral immunity, on a rat spinal cord injury (SCI) model with immunohistochemical methods. mAterIAl and methOds: Twenty-four rats were used for the study. Rats were divided as control, SCI, and rituximab-treated SCI groups. Intraperitoneal rituximab administration was performed on days 0, 3 and 5 in the third group. Rats were sacrificed 7 days after trauma. Antibodies against IL-1β, IL-6, TNF-α and CD20 were studied with the ELISA method together with electron microscopic analysis. results: It was found that rituximab suppressed oligodendrocytes at the phagocytic stage but was still inefficient for the regenerative phase. TNF-α expression was markedly increased in rats subjected to SCI and suppressed after rituximab treatment. Decreased CD20 expression was another prominent finding in rats under rituximab therapy. However, expressions of IL-1β and IL-6 were both increased in glial cells without significant change after rituximab administration. COnClusIOn: TNF-α expression was augmented at the level of SCI both in neuronal and glial cells, particularly in oligodendrocytes. All were suppressed after rituximab administration and rituximab reduced CD20 expression both in neuronal and supportive glial cells which may be related to neural healing.

Özet

AmAÇ: Bu çalışmanın amacı spinal kord hasarı (SKH) modeli oluşturulan ratlarda bir B hücresi monoclonal antikoru olan rituksimabın nöroprotektif etkisinin immünhistokimyasal olarak araştırılmasıdır. yÖntem ve GereÇler: Bu çalışmada, 24 adet rat kullanıldı. Ratlar kontrol, yalnızca SKH ve SKH+ Rituksimab tedavisi alanlar olmak üzere 3 gruba ayrıldı. Tedavi grubuna 0,3 ve 5. gün intraperitoneal olarak rituksimab verildi. Ratlar travmadan 7 gün sonra sakrifiye edildi. ELISA yöntemi ile IL-1β, IL-6, TNF-α ve CD20 antikorları ile immünhistokimyasal ve elektron mikroskopik olarak incelendi. BulGulAr: Bulgular rituksimab uygulamasının oligodentrositlerde fagositik süreci baskıladığını, ancak rejenerasyon fazında yetersiz kaldığını göstermiştir. SKH sonrasında Rituksimab tedavisi ile TNF-α ekspresyonunun tamamen baskılandığı saptanmıştır. Yine rituksimab tedavisi alan ratlarda azalmış CD20 ekspresyonu belirgin bir bulguydu. Glial hücrelerde IL-1β ve IL-6 ekspresyonunun arttığı ancak rituksimab tedavisiyle herhangi bir değişiklik oluşmadığı gözlendi. sOnuÇ: SKHda özellikle oligodendrositlerde belirgin olmak üzere tüm nöronal ve glia hücrelerinde TNF-α ekspresyonunun arttığı görüldü. Bu bulguların rituksimab uygulaması ile tamamen baskılandığı saptandı. Ayrıca rituksimab tedavisi ile nöronal hücrelerle birlikte destekleyici glial hücrelerde görülen azalmış olan CD20 ekspresyonu saptandı. Bu bulgu da nöral iyileşme ile ilişkili olabilir.

🔖

Cite This Article

MENEKŞE, G., DAĞLIOĞLU, E., NACAR, O. A., POLAT, E., ÖZDÖL, Ç., DALGIÇ, A., KAPLANOĞLU, G. T., ÖKTEN, A. İ., BELEN, A. D. (2013). Rat Spinal Kord Hasarında Rituksimabın Nöroprotektif Etkileri: Bir İmmünohistokimyasal Çalışma. Turkish Neurosurgery, Cilt: 23 - Sayı: 6, 783–790. https://ajindex.com/articles/404982

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, Yong VW, Nuttall RK, Pennington CJ, Edwards DR, Bar-Or A: Determinants of human B cell migration across brain endothelial cells. J Immunol 170:4497-4505, 2003 2. Ankeny DP, Lucin KM, Sanders VM, McGaughy VM, Popovich PG: Spinal cord injury triggers systemic autoimmunity: Evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem 99:1073-1087, 2006 3. Ankeny DP, Popovich PG: B cells and autoantibodies: Complex roles in CNS injury. Trends Immunol 31:332-338, 2010 4. Burney RE, Maio RF, Maynard F, Karunas R: Incidence, characteristics, and outcome of spinal cord injury at trauma centers in North America. Arch Surg 128:596-599,1993 5. Campagnolo DI, Keller SE, DeLisa JA, Glick TJ, Sipski ML, Schleifer SJ: Alteration of immune system function in tetraplegics. A pilot study. Am J Phys Med Rehabil 73: 387-393, 1994 6. Dalakas MC: B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 4:557-567, 2008 7. Dumont AS, Dumont RJ, Oskouian RJ: Will improved understanding of the pathophysiological mechanisms involved in acute spinal cord injury improve the potential for therapeutic intervention? Curr Opin Neurol 15:713-720, 2002 8. Dumont RJ, Okonkwo DO, Verma S, Hurlbert RJ, Boulos PT, Ellegala DB, Dumont AS: Acute spinal cord injury, part I: Pathophysiologic mechanisms. Clin Neuropharmacol 24: 254-264, 2001 9. Hayes KC, Hull TC, Delaney GA, Potter PJ, Sequeira KA, Campbell K, Popovich PG: Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 19:753-761, 2002 10. Jones TB, Basso DM, Sodhi A, Pan JZ, Hart RP, MacCallum RC, Lee S, Whitacre CC, Popovich PG: Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: Implications for autoimmune vaccine therapy. J Neurosci 22: 2690-2700, 2002 11. Kosmidis ML, Dalakas MC: Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 3:93-105, 2010 12. Mizrachi Y, Ohry A, Aviel A, Rozin R, Brooks ME, Schwartz M: Systemic humoral factors participating in the course of spinal cord injury. Paraplegia 21:287-293, 1983 13. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T: Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76: 1310